Avoid These 2 Recently Downgraded Stocks

: ATHA | Athira Pharma Inc. News, Ratings, and Charts

ATHA – With the increasing odds of a recession and the expected continuation of the bear market, it could be difficult for fundamentally weak stocks to find support anytime soon. Our proprietary rating system has recently downgraded Athira Pharma (ATHA) and Futu Holdings (FUTU) to Sell because of their weak financials and growth prospects. So, these stocks are best avoided now. Read more….

The stock market has remained under pressure lately due to concerns over surging inflation and the Fed’s aggressive monetary policy tightening. Investors worry that the Federal Reserve’s aggressive interest rate increases to tame the multi-decade high inflation may trigger an economic slowdown.

Moreover, the continued Russia-Ukraine crisis, skyrocketing energy and commodity prices, and lingering supply chain disruptions are making investors pull money out of the stock market. The S&P 500 finished its worst first half in 52 years.

Given this backdrop, fundamentally weak stocks Athira Pharma, Inc. (ATHA) and Futu Holdings Limited (FUTU) could plunge further. Our proprietary POWR Ratings system has recently downgraded these stocks from Neutral to Sell. So, these stocks are best avoided now.

Athira Pharma, Inc. (ATHA)

ATHA is a late clinical-stage biopharmaceutical company that focuses on developing small molecules to restore neuronal health and slow neuron degradation. The company’s lead product candidate is ATH-1017, a blood-brain barrier-penetrating, small molecule HGF/MET positive modulator.

ATHA’s operating loss increased 116.9% year-over-year to $23.39 million for the fiscal year ended December 31, 2022. The company’s net loss grew 136.6% year-over-year to $20.98 million in the quarter. Its loss per share for the quarter came in at $0.56, up 124% year-over-year.

Analysts expect ATHA’s EPS to decline 68.4% for the quarter ending June 30, 2022, and 78.5% in fiscal 2022. Moreover, analysts expect its EPS to remain negative in the current and next year. The stock has lost 76.6% year-to-date to close yesterday’s trading session at $3.05.

ATHA’s poor prospects are apparent in its POWR Ratings also. The stock has an overall rating of D, equating to a Sell in our proprietary rating system. The POWR Ratings assess stocks by 118 different factors, each with its own weighting.

It has an F grade for Sentiment and a D grade for Growth, Momentum, Stability, and Quality. Click here to see the additional POWR Ratings for ATHA (Value). It is ranked #371 out of 398 stocks in the F-rated Biotech industry.

Futu Holdings Limited (FUTU)

Hong Kong-based FUTU operates an online brokerage and wealth management platform internationally. The company provides trading, clearing, and settlement services; margin financing and securities lending services; and a stock yield enhancement program. 

FUTU’s revenue decreased 25.6% year-over-year to $209.50 million in the first quarter ended March 31, 2022. The company’s gross profit declined 19.8% year-over-year to $180.40 million, while its adjusted net income came in at $79.40 million, representing a 47.2% year-over-year decrease.

For fiscal 2022, analysts expect FUTU’s EPS and revenue to decrease 3.4% and 7.7% year-over-year to $2.35 and $839.30 million, respectively. The stock lost 70.9% over the past year to close yesterday’s trading session at $52.21.

FUTU’s POWR Ratings are consistent with this bleak outlook. The stock has an overall rating of D, equating to a Sell in our proprietary rating system. In addition, the stock has a D grade for Stability and Value.

Click here to see FUTU’s Momentum, Quality, Growth, and Sentiment ratings. In addition, FUTU is ranked #11 out of 12 stocks in the F-rated Financial Marketplaces industry.

Want More Great Investing Ideas?

3 Stocks to DOUBLE This Year


ATHA shares were trading at $3.22 per share on Friday afternoon, up $0.17 (+5.57%). Year-to-date, ATHA has declined -75.29%, versus a -19.15% rise in the benchmark S&P 500 index during the same period.


About the Author: Nimesh Jaiswal


Nimesh Jaiswal's fervent interest in analyzing and interpreting financial data led him to a career as a financial analyst and journalist. The importance of financial statements in driving a stock’s price is the key approach that he follows while advising investors in his articles. More...


More Resources for the Stocks in this Article

TickerPOWR RatingIndustry RankRank in Industry
ATHAGet RatingGet RatingGet Rating
FUTUGet RatingGet RatingGet Rating

Most Popular Stories on StockNews.com


Investors: Are You Ready for November?

The S&P 500 (SPY) tumbled to end October. Is that a harbinger of more downside to come? Or will the bull market return with gusto? Investment pro Steve Reitmeister shares his time market views including a preview of his favorite stocks. Get the full story below...

3 Cybersecurity Stocks Defending Against Digital Threats

The demand for cybersecurity solutions is rising as digital threats and sophisticated cyberattacks continue to escalate. Therefore, it might be wise to keep track of cybersecurity stocks, CrowdStrike (CRWD), Palo Alto Networks (PANW), and Fortinet (FTNT), as they offer innovative solutions presenting further growth opportunities. Continue reading...

3 Oil Stocks With High Upside as Global Demand Rebounds

The outlook for oil demand growth appears promising despite economic uncertainties and worldwide supply deficit. Amid this, investing in quality oil stocks Enterprise Products Partners (EPD), Marathon Oil (MRO), and Plains All American Pipeline (PAA) could be ideal as global demand rebounds. Read more...

3 Tech Stocks Under $10 That Could Deliver Big Gains

The technology industry is booming, driven by breakthroughs and significant government investments. Thus, incorporating affordable tech stocks, Sprinklr (CXM), Sabre Corporation (SABR), and Cricut (CRCT) into your portfolio provides an accessible entry point to capitalize on the industry’s growth. Read more…

2 Concerns for Investors in October

The S&P 500 (SPY) may be touching all time highs...but recent action points to concerns on 2 fronts: inflation and earnings. Investment veteran Steve Reitmeister shares his views on these 2 timely topics along with a preview of his top stocks to buy now.

Read More Stories

More Athira Pharma Inc. (ATHA) News View All

Event/Date Symbol News Detail Start Price End Price Change POWR Rating
Loading, please wait...
View All ATHA News